Ben Haynor

Steve Perry

Swayampakula Ramakanth

- On **October 16, 2025**, CollPlant Biotechnologies Ltd. announced that Mayo Clinic researchers developed a **first-in-kind fully humanized 3D bioprinted human skin model** using CollPlant's proprietary plant-derived recombinant human collagen (rhCollagen) BioInk.  **[1631487_0001213900-25-099326_ea0261458-6k_collplant.htm:0]** **[1631487_0001213900-25-099326_ea026145801ex99-1_collplant.htm:0]** 
- This innovative model is designed to serve as an **alternative to animal testing** for preclinical research.  **[1631487_0001213900-25-099326_ea026145801ex99-1_collplant.htm:0]** 
- The platform offers a sustainable and ethical solution with broad potential applications in **cosmetic and pharmaceutical testing, disease modeling, and drug development**.  **[1631487_0001213900-25-099326_ea026145801ex99-1_collplant.htm:0]** 
- CollPlant's CEO, Yehiel Tal, highlighted the model's significant advantages, including the ability to produce personalized human skin models at scale and reduce animal testing.  **[1631487_0001213900-25-099326_ea026145801ex99-1_collplant.htm:0]**

CollPlant Biotechnologies (CLGN)